D. Boral Capital Cuts Avita Medical (NASDAQ:RCEL) Price Target to $14.00

Avita Medical (NASDAQ:RCEL) had its price objective lowered by D. Boral Capital from $18.00 to $14.00 in a research report released on Friday,Benzinga reports. The brokerage currently has a buy rating on the stock.

Several other research firms have also recently weighed in on RCEL. Lake Street Capital lowered their price target on Avita Medical from $14.00 to $8.00 and set a “buy” rating on the stock in a report on Monday, August 11th. BTIG Research lowered Avita Medical from a “neutral” rating to a “sell” rating and set a $3.00 price objective for the company. in a report on Friday, August 8th. Finally, Wall Street Zen lowered Avita Medical from a “hold” rating to a “sell” rating in a report on Saturday, August 9th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $11.60.

Avita Medical Stock Performance

Shares of RCEL opened at $4.26 on Friday. The stock’s 50-day simple moving average is $5.20 and its 200 day simple moving average is $6.88. The stock has a market capitalization of $113.40 million, a price-to-earnings ratio of -2.16 and a beta of 1.58. The company has a debt-to-equity ratio of 9.39, a quick ratio of 0.46 and a current ratio of 0.58. Avita Medical has a 52-week low of $3.60 and a 52-week high of $14.16.

Avita Medical (NASDAQ:RCEL) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.12). The company had revenue of $18.42 million for the quarter, compared to analysts’ expectations of $34.27 million. Avita Medical had a negative return on equity of 632.62% and a negative net margin of 68.87%. Avita Medical has set its FY 2025 guidance at EPS. Research analysts forecast that Avita Medical will post -0.95 EPS for the current fiscal year.

Insider Buying and Selling at Avita Medical

In other news, Director Robert Mcnamara acquired 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 28th. The shares were bought at an average cost of $4.50 per share, with a total value of $45,000.00. Following the acquisition, the director owned 86,771 shares in the company, valued at approximately $390,469.50. This represents a 13.03% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Over the last 90 days, insiders bought 24,000 shares of company stock worth $113,660. Company insiders own 2.80% of the company’s stock.

Hedge Funds Weigh In On Avita Medical

Large investors have recently modified their holdings of the company. BNP Paribas Financial Markets purchased a new position in shares of Avita Medical during the 4th quarter valued at about $38,000. CWM LLC raised its holdings in shares of Avita Medical by 1,099.5% during the 1st quarter. CWM LLC now owns 4,918 shares of the company’s stock valued at $40,000 after buying an additional 4,508 shares in the last quarter. GAMMA Investing LLC raised its holdings in shares of Avita Medical by 688.9% during the 1st quarter. GAMMA Investing LLC now owns 6,374 shares of the company’s stock valued at $52,000 after buying an additional 5,566 shares in the last quarter. Meeder Asset Management Inc. purchased a new position in shares of Avita Medical during the 1st quarter valued at about $53,000. Finally, The Manufacturers Life Insurance Company purchased a new position in shares of Avita Medical during the 2nd quarter valued at about $58,000. 27.66% of the stock is owned by hedge funds and other institutional investors.

About Avita Medical

AVITA Medical, Inc, together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions.